stockrowArrowhead Pharmaceuticals, Inc.
ARWR Healthcare Biotechnology
Arrowhead Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended September 2025) was $829.4 million, up 23,258.2% from fiscal 2024.
- Revenue
- +171.0%
- EPS
- −7.94%
- Free cash flow
- −15.4%
- Total debt
- +259.5%
Quarter to June 2026, against a year earlier
Follow ARWR
Alert me
Arrowhead Pharmaceuticals, Inc. (ARWR) Return on invested capital
Arrowhead Pharmaceuticals, Inc.'s return on invested capital over the twelve months to 30 June 2026 was 0.00%, down 0.0 percentage points from fiscal 2025 (0.00%). Over the past ten years it has ranged from −525.8% (fiscal 2015) to 0.00% (fiscal 2025) — the current reading is the highest in ten years. That is in line with the Biotechnology industry median of 0.00% and in line with the Healthcare sector median of 0.00%.
Return on invested capital, annual
Embed this chart
Annual newest first
| Period | Return on invested capital | Change (points) |
|---|---|---|
| FY2025 | 0.00% | 0.00 |
| FY2024 | 0.00% | 47.98 |
| FY2023 | −48.0% | 42.34 |
| FY2022 | −90.3% | 49.59 |
| FY2021 | −139.9% | (105.13) |
| FY2020 | −34.8% | (34.78) |
| FY2019 | 0.00% | 166.22 |
| FY2018 | −166.2% | (36.26) |
| FY2017 | −130.0% | 282.53 |
| FY2016 | −412.5% | 113.31 |
Against its own ten years
Return on invested capital against peers
| Company | Return on invested capital |
|---|---|
| PTGX Protagonist Therapeutics, Inc. compare | 61.8% |
| KRYS Krystal Biotech, Inc. compare | 27.2% |
| CAI Caris Life Sciences,�Inc. compare | 22.2% |
| CORT Corcept Therapeutics Incorporated compare | 15.0% |
| ARWR Arrowhead Pharmaceuticals, Inc. | 0.00% |
| CYTK Cytokinetics, Incorporated compare | 0.00% |
| SYRE Spyre Therapeutics, Inc. compare | 0.00% |
| TWST Twist Bioscience Corporation compare | −30.8% |
| MDGL Madrigal Pharmaceuticals, Inc. compare | −1,480.3% |
| Biotechnology industry median | 0.00% |
| Healthcare sector median | 0.00% |
| Market median | 0.00% |
What Return on invested capital is
Return on Invested Capital shows how much after-tax operating profit a company earns on the money its lenders and shareholders have put in.
TTM: (Operating Income × 0.625) ÷ (Shareholders Equity (Total) (latest quarter) + Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter) − Cash & Short Term Investments (latest quarter)); Annual: (Operating Income × 0.625) ÷ (Shareholders Equity (Total) + Long Term Debt (Total) + Current Part of Debt − Cash & Short Term Investments)
More on ARWR
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- The full statement